Safety, Tolerability, PK&PD of AZD4721(MAD)+ Compare to PD of AZD5069

• Research type

  Research Study

• Full title

  A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study in Male or Female Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral AZD4721 after once daily administration of Multiple Ascending Doses for 10 days, and to compare the Pharmacodynamics with those of one oral dose level of AZD5069 given twice daily for 3 days

• IRAS ID

  137989

• Contact name

  James Ritter

• Contact email

  james.ritter@quintiles.com

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2013-003392-36

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  13/SC/0476

• Date of REC Opinion

  30 Oct 2013

• REC opinion

  Further Information Favourable Opinion